Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 1.00 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.86 |
| ▸ | SCN7A | Q01118 | 2/20 | 0.85 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.85 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.85 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16966901 | 1.00 | SCN9A (1.00) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL16967054 | 0.95 | SCN9A (1.00) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL16967075 | 0.95 | SCN9A (1.00) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL16966867 | 0.95 | SCN9A (1.00) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL16966959 | 0.93 | SCN9A (0.89) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL16966957 | 0.93 | SCN9A (0.89) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL16966962 | 0.93 | SCN9A (0.89) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL16967243 | 0.93 | SCN9A (1.00) | SCN9ASCN10A | |
| SCHEMBL16966881 | 0.92 | SCN9A (1.00) | SCN9ASCN10ASCN7AKCNH2SCN5A | |
| SCHEMBL16966911 | 0.92 | SCN9A (1.00) | SCN9ASCN10ASCN7AKCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226062-A9 | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | ABBVIE INC. | 2017-08-10 | — | — | US | claimed |
| EP-3102569-A1 | 6-HETEROARYLOXY- AND 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND USES THEREOF | AbbVie Inc. (US) | 2016-12-14 | — | — | EP | claimed |
| US-20160355482-A1 | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | ABBVIE INC (US) | 2016-12-08 | — | — | US | claimed |
| US-9452986-B2 | 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use | ABBVIE INC. (US) | 2016-09-27 | — | — | US | claimed |
| WO-2015119998-A1 | 6-HETEROARYLOXY- AND 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND USES THEREOF | ABBVIE, INC. (US) | 2015-08-13 | — | — | WO | claimed |
| US-20150218102-A1 | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | ABBVIE INC. | 2015-08-06 | — | — | US | claimed |
| US-20180334435-A1 | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | ABBVIE INC. | 2018-11-22 | — | — | US | disclosed |
| US-9969693-B2 | 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use | ABBVIE INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170226062-A9 | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | ABBVIE INC. | 2017-08-10 | — | — | US | disclosed |
| US-20160355482-A1 | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | ABBVIE INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-9452986-B2 | 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use | ABBVIE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150218102-A1 | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | ABBVIE INC. | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226062-A9 | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | SCN8A, SCN7A, SCN2A | SCN9A 21/4885SCN10A 14/4885SCN7A 2/4885 |
| US-20180334435-A1 | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | SCN8A, SCN7A, SCN2A | SCN9A 21/4885SCN10A 14/4885SCN7A 2/4885 |
| US-20160355482-A1 | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | SCN8A, SCN7A, SCN2A | SCN9A 21/4885SCN10A 14/4885SCN7A 2/4885 |
| US-20150218102-A1 | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | SCN8A, SCN7A, SCN2A | SCN9A 21/4885SCN10A 14/4885SCN7A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.